DSS reports going concern audit opinion
The qualification was included in its fiscal 2025 annual report filed March 31, 2026, disclosed per NYSE rules.
See the latest news and media coverage for DSS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Diversified holding company
dssworld.comLast updated
In short: DSS reported significant revenue growth and completed the spin-out of its biotech subsidiary despite receiving a going concern audit opinion.
The qualification was included in its fiscal 2025 annual report filed March 31, 2026, disclosed per NYSE rules.
The spin-out increases visibility and value, now pursuing a reverse merger.
The letter details cost reductions, revenue growth, and strategic initiatives like the Impact BioMedical spin-out.
Gross proceeds were $1.0 million from 900,000 shares at $1.00 per share. Net proceeds will be used for general corporate purposes.
Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc. on a Future...
An announcement from DSS ( (DSS)) is now available. On February 4, 2026, DSS, Inc. priced a firm-commitment underwritten public offering of 900,000 shares of...
DSS, Inc. (NYSE American: DSS) today announced that it has withdrawn its previously filed Registration Statement on Form S-1 with the U.S. Securities and Exchange...
Detailed price information for Document Security Systems (DSS-A) from The Globe and Mail including charting and trades.
Track DSS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to DSS and other trending companies.